IL2 and ovarian cancer: The lack of clinical activity of the anti-CD25 mAb daclizumab given in combination with cancer vaccines to patients with melanoma or ovarian cancer was hypothesized to be linked to the detrimental effects of the IL-2 signaling blockade on cytotoxic Teffs (10, 11).